EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Astragaloside IV, as a potential anticancer agent

Dongqin Xia, Wenjie Li, Ce Tang, Juan Jiang

Frontiers in Pharmacology · 17.02.2023 · 14

DOI: 10.3389/fphar.2023.1065505 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.02.2023. Verfasst von Dongqin Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing University Cancer Hospital, Chongqing, China. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus . AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM.

Schlagwörter

Stichwörter der Autor:innen

AS-IVanticancerastragaloside IVnatural productsaponin

Autor:innen und Institutionen

  • Chongqing University Cancer Hospital, Chongqing, China.
  • Affiliated Hospital of Northwest Minzu University, Lanzhou, China.
  • State Key Laboratory of Southwestern Chinese Medicine Resources, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Zitieren

APA

Xia, D., Li, W., Tang, C., & Jiang, J. (2023). Astragaloside IV, as a potential anticancer agent. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1065505

Vancouver

Xia D, Li W, Tang C, Jiang J. Astragaloside IV, as a potential anticancer agent. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1065505

BibTeX
@article{Xia2023,
  author = {Xia, Dongqin and Li, Wenjie and Tang, Ce and Jiang, Juan},
  title = {Astragaloside IV, as a potential anticancer agent},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1065505}
}
Kostenlos starten →